Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum COSCIENS Biopharma Inc T.CSCI

Alternate Symbol(s):  CSCI

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone... see more

TSX:CSCI - Post Discussion

COSCIENS Biopharma Inc > GLP-1 & Oat-zempic
View:
Post by prophetoffactz on Sep 13, 2024 7:22am

GLP-1 & Oat-zempic

Gilles Gagnon commented on CZO's oat beta glucan pill clinical trial:

"...continued efforts may be warranted to explore its effect on weight and body-mass index with prolonged exposure and possibly higher dosage"

While the weight loss effects were not statistically significant, the company views these preliminary findings as potentially promising and worthy of further investigation. 


Perplexity Ai:

Based on the research findings, oat beta-glucan appears to act as a natural stimulator of GLP-1 (glucagon-like peptide-1) release, though not as potently as synthetic GLP-1 agonist drugs like Ozempic (semaglutide). Here are the key points:
  1. Oat beta-glucan is a type of dietary fiber found naturally in oats and barley.
  2. Consuming beta-glucan can lead to increased production of short-chain fatty acids like butyrate in the gut.
  3. Butyrate stimulates the release of GLP-1 from intestinal L cells.
  4. GLP-1 is a hormone that helps suppress appetite, slow gastric emptying, and improve glucose control.
  5. While oat beta-glucan can trigger natural GLP-1 release, its effects are much less potent than synthetic GLP-1 agonist drugs like Ozempic.
  6. Studies have shown that beta-glucan consumption can lead to improvements in weight management, glucose control, and feelings of fullness, likely partly through this GLP-1 mechanism.
  7. However, the "oat-zempic" trend of using oats as a substitute for Ozempic is considered "wildly overblown" by experts, as the effects are not comparable in magnitude.
In summary, oat beta-glucan can be considered a natural way to stimulate some GLP-1 release, but it is not a direct GLP-1 agonist like Ozempic. Its effects on weight and glucose control, while beneficial, are more modest than those of pharmaceutical GLP-1 agonists.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities